On April 1, 2020, the FDA issued a recall of the following Zantac products: Zantac ranitidine, Zantac prescription sleep aid, Zantaceren topical product, Zantac extended release tablets, Zantac oral liquid, and Zantac extended release capsule. The recalled products include the following medications: Zantac 10 mg, Zantac extended release tablet, Zantac liquid and capsules, Zantac oral liquid, Zantac extended release, Zantac caplets, and Zantac substrate preparation. It is believed that the combination of these products with sedatives may have resulted in the unintentional death of some patients. It is important to contact the manufacturer and the medical provider if one of these products are consumed. Read more here for added understanding.
On September 8, Zantac announced that it was recalling additional products in the future. These additional products included Zantac platinum liquid, Zantac extended release capsule, Zantac caplets, and Zantac substrate preparation. No illnesses or injuries have been reported as a result of the recalled products. At this time, it is not known whether these products were properly packed.
On March 7, FDA released the results of a Zantac recall. The recalled products were the Zantac 10 mg, Zantac prescription sleep aid, Zantac extended release tablet, Zantac liquid and capsules, Zantac oral liquid, and Zantac estate preparation. Based on the contents of the recall reports, the following potential adverse reactions were identified for the products in the recalled distribution: serious respiratory depression with fever, difficulty breathing or coughing, seizures, and chest pain. The most probable cause of these reactions was the use of high temperatures during the manufacturing process of these Zantac products, which resulted in formation of a substance called benzene.
On March 5, the FDA sent a letter to healthcare providers advising them of the Zantac medications that were recalled. The letters advised these healthcare providers to stop prescribing Zantac to patients who are currently taking another prescription medication that may interact with Zantac. The drugs in this recall include Butoconazole, Nylar, and Phenergan. The FDA is not aware of any serious incidents or death associated with these drugs. Zantac has received reports of patient deaths related to anesthesia, but those cases have since been ruled inadmissible by the courts. In addition, no patient has died due to taking Zantac, and the company is not aware of any patient ever dying from taking this medication.
On March 9, the FDA notified pharmaceutical manufacturers and herbal supplement companies that they had issued a Zantac Recall. According to the FDA, all the products in the recall were distributed to pharmacies and were distributed without a medical device distributor permit or indication. The recalled products included bupropion, acamprosate, camporex, Demerol, levorotep, methylphenidate, propoxur, sulfamethoxazole, and stadol.
A letter from the FDA also advised retailers and vendors of the recalled products, not to sell or distribute Zantac to anyone without a physician's prescription. The manufacturer of the product is expected to issue a corrective order to distributors within one week. It is unknown when a final determination will be made about the other products that were involved in the Zantac Recall. A number of new drugs have already been released to the market and additional products are currently being marketed. It is important for patients to contact their health care providers if they have been affected by the Zantac recalled and seek a full review of their condition. Visiting this link will also help you find out more regarding this article.
Gather more added info at https://www.dictionary.com/browse/ranitidine
Comments